IL-8 and its role as a potential biomarker of resistance to anti-angiogenic agents and immune checkpoint inhibitors in metastatic renal cell carcinoma
The therapeutic armamentarium of metastatic Renal Cell Carcinoma (mRCC) has consistently expanded in recent years, with the introduction of VEGF/VEGFR (Vascular Endothelial Growth Factor/Vascular Endothelial Growth Factor Receptor) inhibitors, mTOR (mammalian Target Of Rapamycin) inhibitors and Immu...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-08-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.990568/full |
| _version_ | 1828153966615068672 |
|---|---|
| author | Mimma Rizzo Luca Varnier Gaetano Pezzicoli Marta Pirovano Laura Cosmai Camillo Porta Camillo Porta |
| author_facet | Mimma Rizzo Luca Varnier Gaetano Pezzicoli Marta Pirovano Laura Cosmai Camillo Porta Camillo Porta |
| author_sort | Mimma Rizzo |
| collection | DOAJ |
| description | The therapeutic armamentarium of metastatic Renal Cell Carcinoma (mRCC) has consistently expanded in recent years, with the introduction of VEGF/VEGFR (Vascular Endothelial Growth Factor/Vascular Endothelial Growth Factor Receptor) inhibitors, mTOR (mammalian Target Of Rapamycin) inhibitors and Immune Checkpoint (IC) inhibitors. Currently, for the first-tline treatment of mRCC it is possible to choose between a VEGFR-TKI (VEGFR-Tyrosine Kinase Inhibitor) monotherapy, an ICI-ICI (Immune Checkpoint Inhibitor) combination and an ICI-VEGFRTKI combination. However, a consistent part of patients does not derive benefit from first-line therapy with ICIs; moreover, the use of combination regimens exposes patients to significant toxicities. Therefore, there is a critical need to develop prognostic and predictive biomarkers of response to VEGFR-TKIs and ICIs, and measurement of serum IL-8 is emerging as a potential candidate in this field. Recent retrospective analyses of large phase II and phase III trials found that elevated baseline serum IL-8 correlated with higher levels of tumor and circulating immunosuppressive myeloid cells, decreased T cell activation and poor response to treatment. These findings must be confirmed in prospective clinical trials; however, they provide evidence for a potential use of serum IL-8 as biomarker of resistance to VEGFR-TKIs and ICIs. Considering the amount of new agents and treatment regimens which are transforming the management of metastatic renal cell carcinoma, serum IL-8 could become a precious resource in tailoring the best therapy for each individual patient with the disease. |
| first_indexed | 2024-04-11T22:33:31Z |
| format | Article |
| id | doaj.art-eeef596200f6422c87d1506e13f5b681 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-11T22:33:31Z |
| publishDate | 2022-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-eeef596200f6422c87d1506e13f5b6812022-12-22T03:59:18ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-08-011210.3389/fonc.2022.990568990568IL-8 and its role as a potential biomarker of resistance to anti-angiogenic agents and immune checkpoint inhibitors in metastatic renal cell carcinomaMimma Rizzo0Luca Varnier1Gaetano Pezzicoli2Marta Pirovano3Laura Cosmai4Camillo Porta5Camillo Porta6Division of Medical Oncology, Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari, Bari, ItalyDepartment of Pediatrics, Meyer’ Childrens University Hospital, Florence, ItalyDepartment of Interdisciplinary Medicine, School of Medicine, University of Bari “A. Moro”, Bari, ItalyDivision of Nephrology and Dialysis, Azienda Socio-Sanitaria Territoriale (ASST) Fatebenefratelli-Sacco, Fatebenefratelli Hospital, Milan, ItalyDivision of Nephrology and Dialysis, Azienda Socio-Sanitaria Territoriale (ASST) Fatebenefratelli-Sacco, Fatebenefratelli Hospital, Milan, ItalyDivision of Medical Oncology, Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari, Bari, ItalyChair of Oncology, Interdisciplinary Department of Medicine, University of Bari “A. Moro”, Bari, ItalyThe therapeutic armamentarium of metastatic Renal Cell Carcinoma (mRCC) has consistently expanded in recent years, with the introduction of VEGF/VEGFR (Vascular Endothelial Growth Factor/Vascular Endothelial Growth Factor Receptor) inhibitors, mTOR (mammalian Target Of Rapamycin) inhibitors and Immune Checkpoint (IC) inhibitors. Currently, for the first-tline treatment of mRCC it is possible to choose between a VEGFR-TKI (VEGFR-Tyrosine Kinase Inhibitor) monotherapy, an ICI-ICI (Immune Checkpoint Inhibitor) combination and an ICI-VEGFRTKI combination. However, a consistent part of patients does not derive benefit from first-line therapy with ICIs; moreover, the use of combination regimens exposes patients to significant toxicities. Therefore, there is a critical need to develop prognostic and predictive biomarkers of response to VEGFR-TKIs and ICIs, and measurement of serum IL-8 is emerging as a potential candidate in this field. Recent retrospective analyses of large phase II and phase III trials found that elevated baseline serum IL-8 correlated with higher levels of tumor and circulating immunosuppressive myeloid cells, decreased T cell activation and poor response to treatment. These findings must be confirmed in prospective clinical trials; however, they provide evidence for a potential use of serum IL-8 as biomarker of resistance to VEGFR-TKIs and ICIs. Considering the amount of new agents and treatment regimens which are transforming the management of metastatic renal cell carcinoma, serum IL-8 could become a precious resource in tailoring the best therapy for each individual patient with the disease.https://www.frontiersin.org/articles/10.3389/fonc.2022.990568/fullIL-8biomarker of resistanceanti-angiogenic agentimmune checkpoint inhibitorskidney cancer |
| spellingShingle | Mimma Rizzo Luca Varnier Gaetano Pezzicoli Marta Pirovano Laura Cosmai Camillo Porta Camillo Porta IL-8 and its role as a potential biomarker of resistance to anti-angiogenic agents and immune checkpoint inhibitors in metastatic renal cell carcinoma Frontiers in Oncology IL-8 biomarker of resistance anti-angiogenic agent immune checkpoint inhibitors kidney cancer |
| title | IL-8 and its role as a potential biomarker of resistance to anti-angiogenic agents and immune checkpoint inhibitors in metastatic renal cell carcinoma |
| title_full | IL-8 and its role as a potential biomarker of resistance to anti-angiogenic agents and immune checkpoint inhibitors in metastatic renal cell carcinoma |
| title_fullStr | IL-8 and its role as a potential biomarker of resistance to anti-angiogenic agents and immune checkpoint inhibitors in metastatic renal cell carcinoma |
| title_full_unstemmed | IL-8 and its role as a potential biomarker of resistance to anti-angiogenic agents and immune checkpoint inhibitors in metastatic renal cell carcinoma |
| title_short | IL-8 and its role as a potential biomarker of resistance to anti-angiogenic agents and immune checkpoint inhibitors in metastatic renal cell carcinoma |
| title_sort | il 8 and its role as a potential biomarker of resistance to anti angiogenic agents and immune checkpoint inhibitors in metastatic renal cell carcinoma |
| topic | IL-8 biomarker of resistance anti-angiogenic agent immune checkpoint inhibitors kidney cancer |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.990568/full |
| work_keys_str_mv | AT mimmarizzo il8anditsroleasapotentialbiomarkerofresistancetoantiangiogenicagentsandimmunecheckpointinhibitorsinmetastaticrenalcellcarcinoma AT lucavarnier il8anditsroleasapotentialbiomarkerofresistancetoantiangiogenicagentsandimmunecheckpointinhibitorsinmetastaticrenalcellcarcinoma AT gaetanopezzicoli il8anditsroleasapotentialbiomarkerofresistancetoantiangiogenicagentsandimmunecheckpointinhibitorsinmetastaticrenalcellcarcinoma AT martapirovano il8anditsroleasapotentialbiomarkerofresistancetoantiangiogenicagentsandimmunecheckpointinhibitorsinmetastaticrenalcellcarcinoma AT lauracosmai il8anditsroleasapotentialbiomarkerofresistancetoantiangiogenicagentsandimmunecheckpointinhibitorsinmetastaticrenalcellcarcinoma AT camilloporta il8anditsroleasapotentialbiomarkerofresistancetoantiangiogenicagentsandimmunecheckpointinhibitorsinmetastaticrenalcellcarcinoma AT camilloporta il8anditsroleasapotentialbiomarkerofresistancetoantiangiogenicagentsandimmunecheckpointinhibitorsinmetastaticrenalcellcarcinoma |